EUVIMEDEUVIMED entdecken
Crossref

Pegylated-Interferon and Ribavirin for Chronic Hepatitis C Virus Infection in Decompensated Cirrhotics Awaiting Liver Transplantation

B.E. Annicchiarico

The Open Transplantation Journal · 2011

DOI: 10.2174/1874418401105010032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Open Transplantation Journal, 2011. Verfasst von B.E. Annicchiarico.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sustained virologic response (SVR) to the antiviral therapy for chronic hepatitis C virus infection before liver transplantation (LT) can prevent graft infection.Pegylated (PEG)-interferon (IFN) may ameliorate the SVR, improving the risk-to-benefit ratio of antiviral therapy in cirrhotics awaiting LT.From January 2001 to March 2009, 21 HCVinfected cirrhotics eligible for LT were treated with PEG-IFN alpha-2b (1.5 µg/kg weight/week) and ribavirin (800-1200 mg/day).Mean age was 53.7±7.9 years.There were 11 men.Eleven had genotype 1b.Child-Pugh score was 9.5±1.2,Model for End-Stage Liver Disease score 16.6±1.8.Besides virologic failure, full dosage and planned length of therapy were tolerated in 5 patients (23.8%).Adverse events occurred in all patients, life-threatening in 9 (42.9%).No patient died during treatment.Adverse events caused treatment withdrawal in 11 patients (52.4%), ribavirin and/or PEG-IFN reduction in 7 (33.3%).On an intention-to-treat basis, SVR was obtained in 4 patients (19.0%).None of the genotype 1 or 3 patients obtained SVR; 50.0% of genotype 2 patients obtained SVR.All patients with SVR experienced rapid virological response (RVR).Six patients (three nonresponders, two relapsers, one sustained responder) were transplanted; six died; four are awaiting LT; two are under evaluation for listening; three refused LT.The risk-to-benefit ratio is against treatment with PEG-IFN and ribavirin of severely decompensated genotype 1 cirrhotics.In contrast, antiviral therapy is probably beneficial in genotype 2 subjects, due to an expected SVR rate of 50%.However, one must carefully consider the high risk for severe adverse events.

Zitieren

APA

Annicchiarico, B. (2011). Pegylated-Interferon and Ribavirin for Chronic Hepatitis C Virus Infection in Decompensated Cirrhotics Awaiting Liver Transplantation. The Open Transplantation Journal. https://doi.org/10.2174/1874418401105010032

Vancouver

Annicchiarico B. Pegylated-Interferon and Ribavirin for Chronic Hepatitis C Virus Infection in Decompensated Cirrhotics Awaiting Liver Transplantation. The Open Transplantation Journal. 2011. doi:10.2174/1874418401105010032

BibTeX
@article{Annicchiarico2011,
  author = {Annicchiarico, B.E.},
  title = {Pegylated-Interferon and Ribavirin for Chronic Hepatitis C Virus Infection in Decompensated Cirrhotics Awaiting Liver Transplantation},
  journal = {The Open Transplantation Journal},
  year = {2011},
  doi = {10.2174/1874418401105010032}
}
Kostenlos starten →